473 related articles for article (PubMed ID: 33319649)
1. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Tuccori M; Ferraro S; Convertino I; Cappello E; Valdiserra G; Blandizzi C; Maggi F; Focosi D
MAbs; 2020; 12(1):1854149. PubMed ID: 33319649
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
Yue S; Li Z; Lin Y; Yang Y; Yuan M; Pan Z; Hu L; Gao L; Zhou J; Tang J; Wang Y; Tian Q; Hao Y; Wang J; Huang Q; Xu L; Zhu B; Liu P; Deng K; Wang L; Ye L; Chen X
Front Immunol; 2021; 12():751584. PubMed ID: 34630430
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
VanBlargan LA; Errico JM; Halfmann PJ; Zost SJ; Crowe JE; Purcell LA; Kawaoka Y; Corti D; Fremont DH; Diamond MS
Nat Med; 2022 Mar; 28(3):490-495. PubMed ID: 35046573
[TBL] [Abstract][Full Text] [Related]
5. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Focosi D; Maggi F
Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631
[TBL] [Abstract][Full Text] [Related]
6. What do we know about the antibody responses to SARS-CoV-2?
Lagunas-Rangel FA; Chávez-Valencia V
Immunobiology; 2021 Mar; 226(2):152054. PubMed ID: 33524881
[TBL] [Abstract][Full Text] [Related]
7. Development and application of therapeutic antibodies against COVID-19.
Ning L; Abagna HB; Jiang Q; Liu S; Huang J
Int J Biol Sci; 2021; 17(6):1486-1496. PubMed ID: 33907512
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC; Adams AC; Hufford MM; de la Torre I; Winthrop K; Gottlieb RL
Nat Rev Immunol; 2021 Jun; 21(6):382-393. PubMed ID: 33875867
[TBL] [Abstract][Full Text] [Related]
9. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
10. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
11. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
[TBL] [Abstract][Full Text] [Related]
12. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
13. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
[TBL] [Abstract][Full Text] [Related]
14. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
VanBlargan L; Errico J; Halfmann P; Zost S; Crowe J; Purcell L; Kawaoka Y; Corti D; Fremont D; Diamond M
Res Sq; 2021 Dec; ():. PubMed ID: 34981042
[TBL] [Abstract][Full Text] [Related]
15. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.
Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R
BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic monoclonal antibodies for COVID-19 management: an update.
Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
[TBL] [Abstract][Full Text] [Related]
17. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
18. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
19. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
Barnes TW; Schulte-Pelkum J; Steller L; Filchtinski D; Jenness R; Williams MR; Kober C; Manni S; Hauser T; Hahn A; Kalina U; Simon TL; Schuetz P; Roth NJ
Clin Immunol; 2021 Nov; 232():108871. PubMed ID: 34619377
[TBL] [Abstract][Full Text] [Related]
20. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
